drugset / Trial / NCT01736943
Bortezomib and Doxil for the Treatment of Patients With Acute Myelogenous Leukemia
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether bortezomib in combination with doxil/lipodox is effective in the treatment of Acute Myeloid Leukemia.
Timeline
- Start
- 2012-12-19
- Primary completion
- 2019-05-20
- Completion
- 2019-05-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | 1.5 mg/m2 | Subcutaneous |
| Subject | Doxorubicin | Other / unclassified | 40 mg/m2 | Intravenous |